Introduction
============

Nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin and indomethacin have been widely used clinically as anti-inflammatory, analgestic agents, but it has been documented that NSAIDs cause gastrointestinal erosions and ulcers as adverse effects \[[@B1], [@B2]\]. Although it has been proposed that a deficiency of endogenous prostaglandins due to inhibition of cyclooxygenase by NSAIDs is involved in these effects \[[@B3]\], the exact pathogenic mechanism remains to be elucidated. Recently, several groups including us reported that rebamipide, a gastroprotective drug, significantly reduced gastric mucosal injury induced by indomethacin in rodents \[[@B4]--[@B7]\] and humans \[[@B8], [@B9]\]. We firstly reported that protective effects of rebamipide against indomethacin-induced gastric mucosal injury may result from its antioxidant effect \[[@B4]\]. In addition, we have demonstrated the gastric cytoprotection induced by rebamipide from a double blind comparative study in healthy volunteers \[[@B8]\].

More recently, we investigated the effect of rebamipide on gene expression in cultured rat gastric mucosal (RGM1) cells exposed to indomethacin \[[@B10]\]. By the analysis using DNA microarray and real-time PCR, we confirmed that the expression of growth arrest and DNA damage-induced 45α (GADD45α) in RGM1 cells is enhanced by the exposure to indomethacin and this enhancement is markedly inhibited by rebamipide. However, the effects of rebamipide on gastric mucosal gene expression *in vivo* have not been fully addressed. In order to characterize the cytoprotective effects of rebamipide on indomethacin-induced gastric mucosal injury, we developed acute gastric mucosal injury induced by indomethacin in rats and measured comprehensive changes in mRNA expression using DNA microarray in the absence and presence of rebamipide.

Materials and Methods
=====================

Reagents
--------

All chemicals were prepared immediately before use. Rebamipide was a gift from Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). RNeasy Mini kit was purchased from QIAGEN (Valencia, CA) and Rat Toxicology GeneChip U34 array and Eukaryotic Small Sample Target Labeling Assay kit were from Affymetrix (Santa Clara, CA). All other chemicals used were of reagent grade.

Preparation of rats for acute gastric mucosal injury induced by indomethacin
----------------------------------------------------------------------------

Male Sprague-Dawley rats weighing 190--210 g were obtained from Keari Co. Ltd. (Osaka, Japan). They were housed in stainless steel cages with wire bottoms and maintained on a 12-h light and 12-h dark cycle with the temperature and relative humidity of the animal room controlled at 21--23°C and 55--65%, respectively. They were not fed for 18 h prior to the experiments, but were allowed free access to water. Maintenance of animals and experimental procedures were carried out in accordance with the U.S. National Institutes of Health Guidelines for the Use of Experimental Animals. All experiments were approved by the Animal Care Committee of Kyoto Prefectural University of Medicine (Kyoto, Japan). Gastric mucosal injury was induced by the oral administration of 25 mg/kg of indomethacin (Sigma Chemical Co., St. Louis, MO) suspended in 0.5% carboxymethyl cellulose (CMC) solution with a few drops of Tween 80 in a volume of 0.5 ml/100 g body weight \[[@B11]\]. According to our previous report \[[@B4]\], rebamipide (100 mg/kg) dissolved in 0.5% CMC solution was given to the rats by intraperitoneal injection 0.5 h before indomethacin administration. To evaluate the effect of agents on indomethacin injury, rats were divided into the following groups: 1) sham-operated rats receiving 0.5% CMC solution, 2) indomethacin-treated rats receiving 0.5% CMC solution, 3) sham-operated rats receiving rebamipide, and 4) indomethacin-treated rats receiving rebamipide. Each of the groups contained 3 rats.

Laser capture microdissection, isolation of RNA, cDNA synthesis, cRNA amplification, and GeneChip hybridization
---------------------------------------------------------------------------------------------------------------

According to our previous report \[[@B12]\], we used laser-assisted microdissection to obtain cell-specific RNA. Gastric epithelial cells, located mainly in an upper one-third of mucosa, were identified on cryostat sections (8 µm) of the specimens obtained from the stomach of the rat, and the cells were isolated by laser-assisted microdissection using an LM200 system (Olympus, Tokyo, Japan). A sample containing five hundred cells was collected from each stomach. Our experiments were performed according to the Affymetrix GeneChip Eukaryotic Small Sample Target Labeling Assay protocol (Version II). Using this protocol, we succeeded in obtaining a sufficient amount of biotinylated cRNA to perform the GeneChip analysis from the small amount of gastric epithelial cells obtained by laser-captured microdissection.

Total RNA was extracted from the mixtures of three samples using a Qiagen RNeasy kit (Qiagen, Valencia, CA) and treated with DNase to remove any residual genomic DNA. Briefly, for first strand cDNA synthesis, total RNA sample (1 µl) mixed with T7-Oligo(dT) promoter primer was incubated at 70°C in a thermal cycler for 6 min, cooled to 4°C for 2 min, and reverse transcribed for 1 h at 42°C with 3 µl of the RT_Premix_1, and cooled to 4°C. Strand cDNA synthesis was carried out by adding 32.5 µl of SS_Premix_1, and incubating for 2 h at 16°C. The resulting cDNA was cleaned up by ethanol precipitation. To perform *in vitro* transcription, the dried double-stranded cDNA pellet was mixed with the following reagents (10 µl): 4 µl DEPC-treated water, 4 µl premixed NTPs, 1 µl 10× reaction buffer, and 1 µl 10× enzyme mix, and incubated at 37°C in a water bath for 6 h. First cycle cRNA was cleaned up using the RNeasy Mini Protocol for RNA Cleanup from the handbook accompanying the RNeasy Mini Kit for cRNA purification. For the second cycle of amplification and labeling, the cRNA sample was mixed with random primers (0.2 µg/µl), incubated at 70°C for 10 min, cooled on ice for 2 min, and incubated at 42°C for 1 h with 5 µl of the RT_Premix_2. Second strand cDNA synthesis was carried out by mixing the sample with by addition of 5 µM T7-Oligo(dT) promoter primer and incubating at 70°C for 6 min, cooling at 4°C, and incubating again with 62 µl of SS_Premix_2. The resulting cDNA was treated with 1 µl T4 DNA polymerase (5 U/µl) for 10 min at 16°C, and cleaned up by ethanol precipitation. To perform *in vitro* transcription and labeling with the ENZO BioArray High Yield RNA Transcript Labeling Kit, the dried double-stranded cDNA pellet was incubated at 37°C for 4 h with 40 µl of the following reagents: 22 µl DEPC-treated water, 4 µl 10× HY reaction buffer, 4 µl 10× biotin labeled ribonucleotides, 4 µl 10× DTT, 4 µl 10× RNase inhibition mix, and 2 µl 20× T7 RNA polymerase. Labeled cRNA target was cleaned up using RNeasy columns.

The fragmentation, hybridization, washing, and staining were carried out according to the instructions described in the GeneChip Expression Analysis Technical Manual. GeneChip arrays were hybridized with the biotinylated products (5 µg/chip) for 16h at 45°C using the manufacturer's hybridization buffer. After washing the arrays, hybridized RNA was detected by staining with streptavidin-phycoerythrin (6 × SSPE, 0.01% Tween-20, pH 7.6, 2 mg/ml acetylated bovine serum albumin, and 10 µg/ml of streptavidin-phycoerythrin from Molecular Probes). The DNA chips were scanned using a specially designed confocal scanner (GeneChip Scanenr 3000, Affymetrix).

Gene expression analysis
------------------------

As an initial statistical analysis, we used Affymetrix GeneChip Operating Software (GCOS) version 1.0. GCOS analyzes image data and computes an intensity value for each probe cell. Briefly, mismatch probes act as specificity controls that allow the direct subtraction of both background and cross-hybridization signals. To determine the quantitative RNA abundance, the average of the difference representing perfect match - mismatch for each gene-specific probe family is calculated. GCOS showed expression changes (Increased, Decreased or Marginal) in expression levels between pairs of profiles (difference analysis). For the pathway analysis, Gene probe set ID numbers were imported into the Ingenuity Pathway Analysis software (Ingenuity Systems, Mountain View, CA). The identified genes were mapped to genetic networks available in the Ingenuity database and were then ranked by score. The score is the probability that a collection of genes equal to or greater than the number in a network could be achieved by chance alone. A score of 3 indicates that there is a 1/1000 chance that the focus genes are in a network due to random chance. Therefore, scores of 3 or higher have a 99.9% confidence of not being generated by random chance alone.

Results and Discussion
======================

Analysis for gene expression induced by indomethacin treatment in rats
----------------------------------------------------------------------

In the present study, we used the high-density oligonucleotide microarray technique for mRNA expression profile of gastric elithelial cells in order to investigate the mechanism of mucosal injury under the conditions of indomethacin exposure *in vivo*. We used the Rat Toxicology GeneChip U34 array (Affymetrix), which contained 1,031 probes. The present study showed that the expression of 160 probes (15.5%) showed at least a 2.0-fold up-regulation (158 probes) or down-regulation (2 probes) 2 h after indomethacin administration in comparison with the vehicle-treated rats. Selective genes demonstrating alterations greater than 3.0-fold are listed in the Table [1](#T1){ref-type="table"}. Genes involved in redox-related enzymes (superoxide dismutase 1, carbonyl reductase 1, glutathione peroxidase 3, glutathione S-transferase, etc.) and transcription regulators (c-fos oncogene, etc.) were included.

123 of these up-regulated 158 probes were mapped to genetic networks as defined by the IPA tool. By the pathway analysis of the up-regulated 123 probes, 5 networks were found to be significant in that they had more of the identified genes present than would be expected by chance (Table [2](#T2){ref-type="table"}). The network 1 shown in Table [2](#T2){ref-type="table"} contained the majority of these genes, and had a highly significant score of 73, and consisted of known clusters of cell death, cancer, and endocrine system disorders. Figure [1](#F1){ref-type="fig"} illustrated the association of the network 1 that was most significantly affected by indomethacin. These data suggest that the imbalance of gene expression between apoptotic- and anti-apoptotic genes may be involved in the pathogenesis of indomethacin-induced gastric mucosal injury, which was also supported by previous studies. It has been demonstrated that indomethacin treatment induces gastric epithelial cell apoptosis *in vivo* \[[@B13], [@B14]\] and *in vitro* \[[@B15], [@B16]\]. Recent our study clearly showed apoptotic cell death of gastric epithelial cells induced by indomethacin *in vitro* \[[@B10]\].

In addition, we found two major pathways by the Ingenuity pathway analysis; glutathione metabolism and inflammation (Table [3](#T3){ref-type="table"}). The genes involved in glutathione metabolism included glutathione peroxidase 1 and 3, many types of glutathione S-transferases (GST), and microsomal glutathione transferase (MGST1, 3) were up-regulated after the indomethacin exposure. The glutathione metabolism, a caronical pathway recorded in this analysis, was markedly affected by indomethacin with a most highest significance of *p* = 1.42 × 10^−7^. This induction of these genes may result from cellular response in gastric epithelial cells against oxidative stress induced by indomethacin administration, or from the direct pharmacological effect of indomethacin. The former hypothesis is supported by several reports \[[@B11], [@B17]--[@B19]\], in which lipid peroxidation was enhanced by indomethacin treatment and indomethacin induced-gastric mucosal injuries were significantly inhibited by the several antioxidants *in vivo*. The induction of these genes may indicate the presence of oxidative stress in the gastric mucosa after the indomethacin administration. Recent investigation clearly demonstrated that oxidative stress was induced by the irreversible inactivation of gastric peroxidase via the direct interaction between indomethacin and gastric peroxidase \[[@B20]\]. Up-regulation of GST genes is also supported by van Lieshout *et al.* \[[@B21]\], who have demonstrated the induction of GST in the stomach by indomethacin in rats. As GST is a family of detoxifying enzymes, the enhancement of GSTs in the stomach may explain in part the anticarcinogenetic properties of nonsteroidal anti-inflammatory drugs including indomethacin.

In addition to glutathione metabolism, inflammation-associated genes were also up-regulated after the indomethacin treatment, which included fos, jun, MAP kinase, MAP kinase kinase, MAP kinase kinase kinase, NF-κB, and STAT. Ingenuity Pathway analysis showed that IL-6 signaling was associated with these genes with a significance of *p* = 3.97 × 10^−6^. Although it has been reported that IL-6 play a significant role in pathogenesis of gastric inflammation induced by *Helicobacter pylori* \[[@B22], [@B23]\], there were no reports investigating the role of IL-6 in indomethacin-induced gastric mucosal injury. Further studies will be necessary to clarify the role of this signaling in the pathogenesis of indomethacin-induced gastric injury.

Effects of Rebamipide on Gene Expression Affected by Indomethacin in Rats
-------------------------------------------------------------------------

We succeeded in listing 10 genes including 2 EST based on the following criteria: genes that are up-regulated at least 2.0-fold after 2-h treatment with indomethacin in comparison with the vehicle-treated rats, and also genes that are down-regulated at least 1.5-fold after pretreatment with rebamipide in comparison with pretreatment with vehicle prior to 2-h exposure to indomethacin (Table [4](#T4){ref-type="table"}). These genes were involved in regulators of NF-κB cascade (FK506-binding protein 1a, and IkBα), oxidative stress response (glutathione peroxidase 3, dihydrofolate reductase), and cell cycle regulators {transforming growth factor, wee 1, and growth arrest and DNA-damage-inducible 45α (GADD45α)}.

The down-regulation of NF-κB cascade by rebamipide is in line with the previous report, in which anti-inflammatory effect of rebamipide is derived from the inhibition of NF-κB cascade \[[@B24], [@B25]\]. The inhibition of the oxidative stress-related genes by rebamipide is also consistent with the data that rebamipide is powerful scavenger of oxygen-derived free radicals \[[@B26], [@B27]\]. These data suggest that cytoprotection by rebamipide against indomethacin-induced gastric injury may be related to its anti-inflammatory and anti-free radical properties.

Finally, in the Rat Toxicology U34 array, four probe sets were included for the GADD45α gene: rc_AI070295_at, rc\_ AI070295_g\_at, L32591mRNA_at, and L32591mRNA_g\_at. The expression of all four probes was up-regulated at least 1.5-fold after indomethacin exposure and down-regulated by the pretreatment with rebamipide (Table [5](#T5){ref-type="table"}). The present data was in line with our previous data obtained from the *in vitro* study, showing that the expression of GADD45α was enhanced by indomethacin exposure and that this enhancement was markedly inhibited by the treatment with rebamipide \[[@B10]\]. These changes were also confirmed by real-time PCR using a gastric mucosal cell line \[[@B10]\]. These data obtained from *in vivo* and *in vitro* studies strongly suggest that GADD45α play a crucial role in indomethacin-induced cell death, and that cytoprotective action of rebamipide may, in part, be mediated by this molecule.

Effects of Rebamipide Treatment on Gene Expression in Normal Rats
-----------------------------------------------------------------

Among the 1031 probes, the number of genes, the expression levels of which increased more than 1.5-fold in rebamipide-treated mucosa, was 44 including 1 EST. Many investigations have demonstrated several factors, including prostaglandins, growth factors, antioxidants, and heat shock proteins, to exert cytoprotection against gastric injuries. Among these cytoprotective factors, the expression of prostaglandin-endoperoxide synthase 1 (cyclooxygenase 1 (*cox-1*)) was up-regulated by the treatment with rebamipide *in vivo* as shown in Table [6](#T6){ref-type="table"}. By an *in vitro* study using gastric epithelial cells, rebamipide treatment increased the expression of *cox-1* by 1.32-fold compared to vehicle treatment (data not shown). These results suggest that cytoprotective effects of rebamipide may be derived, in part, from Cox-1 or its generated prostaglandins. Tarnawski *et al.* \[[@B28]\] previously reported that rebamipide significantly upregulated the proangiogenic genes encoding vascular endothelial growth factor (VEGF), heparin binding epidermal growth-like factor (HB-EGF), fibroblast growth factor receptor-2 (FGFR2), and cyclooxygenase-2 (Cox2), as well as growth promoting genes, including insulin growth factor-1 (IGF-1). However, the enhanced expression of these genes was not re-confirmed in the present study. These difference may be derived the difference between experimental conditions of *in vivo* (the present study) and *in vitro* shown by Tarnawski *et al.* \[[@B28]\].

In conclusion, the present study using GeneChip analysis demonstrated the enhanced expression of apoptosis- and inflammation-related genes in the gastric epithelial cells exposed to indomethacin *in vivo*, and that inhibition of apoptosis-related genes, especially GADD45α by rebamipide is possibly important for its cytoprotective effect against this injury.

![Networks of genes commonly up-regulated after indomethacin administration.](jcbn2007060f01){#F1}

###### 

Genes up-regulated at least 3.0-fold in gastric mucosa exposed to indomethacin

  Probe Set ID                  Description                                               Signal Intensity             
  ----------------------------- --------------------------------------------------------- ------------------ --------- -------
  M74439mRNA_i\_at              ---                                                       180.1              18371.4   78.79
  Y00404_s\_at                  superoxide dismutase 1                                    298.5              3426.9    10.56
  D89070cds_s\_at               carbonyl reductase 1                                      347.5              4341.7    9.85
  rc_AA859372_s\_at             ---                                                       195.1              1347.0    9.19
  X06769cds_g\_at               FBJ murine osteosarcoma viral oncogene homolog            197.7              1906.8    8.00
  rc_AI228738_s\_at             FK506-binding protein 1a /// FK506 binding protein 2      142.6              922.2     7.46
  AFFX_rat_5S_rRNA_at           ---                                                       124.1              688.1     6.50
  rc_AI172411_at                glutathione peroxidase 3                                  477.1              2807.2    6.06
  J02844_s\_at                  carnitine O-octanoyltransferase                           28.2               103.9     6.06
  C06598_at                     similar to binding protein                                298.4              1828.7    4.92
  U39208_at                     cytochrome P450 4F6                                       578.8              2699.1    4.92
  X53428cds_s\_at               glycogen synthase kinase 3 beta                           67.4               267.0     4.59
  rc_AI171506_g\_at             malic enzyme 1                                            39.9               206.2     4.00
  AA848546_at                   similar to programmed cell death 10                       120.2              264.9     4.00
  rc_AI176658_s\_at             heat shock 27kDa protein 1                                154.1              553.6     4.00
  X07467_at                     glucose-6-phosphate dehydrogenase                         272.0              1103.8    3.73
  rc_AI178835_at                mitogen activated protein kinase kinase 1                 70.0               114.2     3.48
  U95727_at                     DnaJ (Hsp40) homolog, subfamily A, member 2               109.3              238.5     3.48
  X04229cds_s\_at               glutathione S-transferase, mu 1                           159.2              578.6     3.48
  D63761_g\_at                  ferredoxin reductase                                      183.9              668.8     3.48
  X77117exon\#1-3_at            Diaphorase 1                                              248.8              610.0     3.48
  rc_AA945054_s\_at             cytochrome b-5                                            271.0              1036.7    3.48
  K01932_f\_at                  glutathione S-transferase A5                              341.3              1250.4    3.48
  M57428_s\_at                  ribosomal protein S6 kinase, polypeptide 1                76.2               215.6     3.25
  rc_AA848545_at                similar to programmed cell death 10                       119.0              288.9     3.25
  X91988_at                     signal transducer and activator of transcription 5B       163.4              454.9     3.25
  L19998_g\_at                  sulfotransferase family 1A, phenol-preferring, member 1   209.1              605.4     3.25
  X63594cds_g\_at               nuclear factor of kappa light chain gene enhancer         269.1              890.6     3.25
  S82820mRNA_s\_at              glutathione S-transferase Yc2 subunit                     282.4              928.6     3.25
  U03388_s\_at                  prostaglandin-endoperoxide synthase 1                     286.2              572.8     3.25
  rc_AI176422_g\_at             electron-transferring-flavoprotein dehydrogenase          287.5              842.7     3.25
  M15114_g\_at                  stearoyl-Coenzyme A desaturase 2                          102.8              468.7     3.03
  U46118_at                     cytochrome P450, family 3, subfamily a, polypeptide 13    138.3              355.6     3.03
  J05035_at                     steroid 5 alpha-reductase 1                               145.2              544.8     3.03
  X62952_at                     vimentin                                                  163.2              454.5     3.03
  M38566mRNA_s\_at              cytochrome P450, family 27, subfamily a, polypeptide 1    163.5              492.3     3.03
  U03491_g\_at                  transforming growth factor, beta 3                        175.1              604.8     3.03
  M33986mRNA_at                 cytochrome P450, family 19, subfamily a, polypeptide 1    186.1              427.7     3.03
  rc_AA925473_at                cell division cycle 42 homolog (S. cerevisiae)            206.3              595.5     3.03
  rc_AA859648_at                DnaJ (Hsp40) homolog, subfamily B, member 1 (predicted)   221.0              730.3     3.03
  D00636Poly_A\_Site\#1_s\_at   diaphorase 1                                              243.0              1035.5    3.03
  L29232_at                     insulin-like growth factor 1 receptor                     244.7              319.3     3.03
  X78848cds_f\_at               glutathione S-transferase A5                              291.6              903.7     3.03
  X70369_s\_at                  collagen, type III, alpha 1                               720.3              1642.2    3.03

###### 

Genes in network induced by indomethacin treatment

  Network ID   Genes in Network                                                                                                                                                                                                                                  Score   Focus Genes   Top Functions
  ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ------------- --------------------------------------------------------------------
  1            APEX1, COL3A1, CRYAB, CYB5, CYCS, FASN, FOS, GADD45A, GAPD, GPX1, GSK3B, GSTA1, GSTM1, GSTM2, GSTP1, HSF1, HSPA1B, HSPB1, HSPB6, IL18, JUN, MAP2K6, MAP3K12, MAPK14, MGST3, MSH2, MYC, ODC1, PAWR, PPIA, Scd2, SOD2, TGFB3, TOP2A, TRAPPC3        73      35            Cell Death, Cancer, Endocrine System Disorders
  2            ADCYAP1, APOC2, ARD1, BAG2, CANX, CCND2, CDC42, CYP19A1, FBXW11, FGF6, GEFT, GPR30, GPX3, HSPA8, HSPB8, IGF1R, KSR, LPL, MAP2K1, MAP2K1IP1, MAPK3, MOS, NAT1, NFKBIA, PBP, PCSK5, POMC, PPP1CB, PTPRR, RB1, RPS6KB1, SOD1, STIP1, UCN, Ugt2b      23      16            Cell Cycle, Cellular Growth and Proliferation, Cancer
  3            ABCC1, AKR1B1, ANGPTL4, ARG1, CEBPA, CROT, CTH, CYP3A7, CYP51A1, DECR1, DIA1, EGR2, FASN, FTCD, GAL, GH1, GHRH, GHRL, HSD17B4, IFNG, Ins1, LPL, ME1, MGST1, MST1R, PPARA, PTPRN, SOCS2, SRD5A1, STAT5B, THRB, UQCRC1, UQCRC2, UQCRH, VIM          21      15            Organismal Development, Nutritional Disease, Lipid Metabolism
  4            ACOX1, AGT, ANGPTL4, COX7A2, COX8A, CYP17A1, CYP27A1, Cyp2c44, CYP2E1, DAD1, EHHADH, ETFDH, FKBP1A, GAL, GPX3, GPX4, HADHA, HADHB, HSD3B1, IDH1, IL4, IL13, IL1R2, LEP, LTC4S, MAOA, PPARG, PTEN, PTGES, PTGS1, RAB10, STK11, TGFB1, Tgtp, XBP1   19      14            Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry
  5            AHR, AIP, APC, BRF1, BUB1, CAMLG, CCS, CSNK1D, CSNK1E, CYP1A1, CYP1A2, CYR61, DHFR, DNASE1, EPHX1, FDXR, G6PD, GSK3B, HSPCB, IFI16, KLF4, MCM7, NFE2, NQO1, PHB, PSMB2, RBL2, RRM2, SHOX, SIM1, TFDP1, TP53, UBE2B, UBTF, UGT1A6                  12      10            Cell Signaling, Drug Metabolism, Cell Cycle

###### 

High level functions most significantly associated with indomethacin-induced gene expression profile

  Canonical Pathway           Focus Gene   Significance   Genes
  --------------------------- ------------ -------------- -----------------------------------------------------------------------------
  Glutathione Metabolism      11/61        1.42 × 10--7   G6PD, GPX1, GPX3, GSTA1, GSTK1, GSTM1, GSTM2, GSTP1, GSTT2, MGST1, MGST3
  IL-6 Signaling              10/68        3.97 × 10--6   CYP19A1, FOS, HSPB1, IL1R, JUN, MAP2K1, MAP2K6, MAPK3, MAPK14, NF-KBIA
  B Cell Receptor Signaling   10/114       3.78 × 10--4   CDC42, GSK3B, JUN, MAP2K1, MAK2K6, MAP3K12, MAPK3, MAPK14, NFKBIA, RPS6K131
  Tryptophan Metabolism       9/98         5.42 × 10--4   CYP19A1, CYP1A1, CYP1A2, CYP3A7, CYP51A1, EHHADH, HADHA, HSD17B4, MADA

###### 

Genes up-regulated at least 2.0-fold in indomethacin treatment and down-regulated at least 1.5-fold in rebamipide treatment

  Probe Set ID        Description                                                                     Signal Intensity            Ratio              
  ------------------- ------------------------------------------------------------------------------- ------------------ -------- -------- -- ------ ------
  rc_AI228738_s\_at   FK506-binding protein 1a /// FK506 binding protein 2                            142.6              922.2    547.4       7.46   0.66
  rc_AI172411_at      glutathione peroxidase 3                                                        477.1              2807.2   1892.2      6.06   0.66
  rc_AA900413_at      dihydrofolate reductase                                                         95.0               349.9    262.4       3.73   0.57
  U03388_s\_at        prostaglandin-endoperoxide synthase 1                                           286.2              572.8    673.0       3.25   0.62
  X63594cds_g\_at     nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha   269.1              890.6    526.8       3.25   0.62
  U03491_g\_at        transforming growth factor, beta 3                                              175.1              604.8    164.2       3.03   0.38
  AFFX-DapX-M_at      ---                                                                             20.7               70.2     42.2        2.83   0.62
  rc_AI178204_at      ---                                                                             55.6               86.5     78.4        2.46   0.66
  D31838_at           wee 1 homolog (S. pombe) (predicted)                                            91.2               174.8    102.0       2.00   0.66
  rc_AI070295_g\_at   growth arrest and DNA-damage-inducible 45 alpha                                 85.4               168.6    109.5       2.00   0.62

###### 

The levels of mRNA expression for growth arrest and DNA damage-inducible gene (GADD45α)

  Probe set ID        Vehicle   Indomethacin   Indomethacin + Rebamipide   Indomethacin/Vehicle        Indomethacin + Rabamipide/Indometahcin          
  ------------------- --------- -------------- --------------------------- ---------------------- ---- ---------------------------------------- ------ ----
  rc_AI070295_at      31.7      61.4           23.5                        1.87                   NC                                            0.44   D
  rc_AI070295_g\_at   85.4      168.6          109.5                       2.00                   I                                             0.62   D
  L32591mRNA_at       284.3     627.3          556.1                       2.64                   I                                             0.93   NC
  L32591mRNA_g\_at    76.5      112.8          60.1                        1.52                   NC                                            0.87   NC

###### 

Genes up-regulated at least 1.5-fold in rebamipide treatment in rats

  Probe Set ID           Description                                               Signal intensity            Ratio   
  ---------------------- --------------------------------------------------------- ------------------ -------- ------- ------
  D89070cds_s\_at        carbonyl reductase 1                                      347.5              5844.1           4.00
  rc_AA859372_s\_at      ---                                                       195.1              1366.7           4.00
  rc_AI171506_g\_at      malic enzyme 1                                            39.9               360.8            4.00
  X07467_at              glucose-6-phosphate dehydrogenase                         272.0              1660.4           3.48
  M58040_at              Transferrin receptor                                      40.9               208.2            3.25
  D00680_at              glutathione peroxidase 3                                  27.2               216.5            2.83
  D16308_at              cyclin D2                                                 203.0              1238.3           2.83
  M19533mRNA_i\_at       peptidylprolyl isomerase A                                81.9               548.2            2.83
  U09793_at              Kirsten rat sarcoma viral oncogene homologue 2 (active)   29.2               184.9            2.64
  rc_AI172411_at         glutathione peroxidase 3                                  477.1              2975.9           2.64
  U03388_s\_at           prostaglandin-endoperoxide synthase 1                     286.2              1255.3           2.64
  D88190_s\_at           serine/threonine kinase 39, STE20/SPS1 homolog (yeast)    439.2              1506.9           2.30
  rc_AI171506_at         malic enzyme 1                                            52.6               312.1            2.30
  U27518_at              UDP-glucuronosyltransferase                               57.8               242.2            2.30
  X70369_s\_at           collagen, type III, alpha 1                               720.3              3777.7           2.30
  rc_AA892234_at         microsomal glutathione S-transferase 3 (predicted)        480.5              1595.6           2.14
  U68562mRNA\#2_s\_at    heat shock protein 1 (chaperonin)                         108.6              466.8            2.14
  X62952_at              vimentin                                                  163.2              484.5            2.14
  X53428cds_s\_at        glycogen synthase kinase 3 beta                           67.4               209.3            2.00
  M24604_g\_at           proliferating cell nuclear antigen                        192.1              1020.3           2.00
  rc_AA963449_s\_at      cytochrome P450, subfamily 51                             58.7               229.2            2.00
  AB010428_s\_at         cytosolic acyl-CoA thioesterase 1                         118.5              519.1            1.87
  AF007107_s\_at         cytochrome b-5                                            90.6               315.6            1.87
  AFFX_Rat_GAPDH_5\_at   glyceraldehyde-3-phosphate dehydrogenase (GAPDH)          202.0              752.8            1.87
  AFFX_Rat_GAPDH_M\_at   glyceraldehyde-3-phosphate dehydrogenase (GAPDH)          493.0              1994.0           1.87
  D89375_s\_at           sulfotransferase family 1B, member 1                      173.4              662.9            1.87
  M17701_s\_at           glyceraldehyde-3-phosphate dehydrogenase (GAPDH)          693.4              2398.9           1.87
  rc_AA899854_at         topoisomerase (DNA) 2 alpha                               224.1              816.7            1.87
  S82820mRNA_s\_at       glutathione S-transferase Yc2 subunit                     282.4              1092.5           1.87
  U95727_at              DnaJ (Hsp40) homolog, subfamily A, member 2               109.3              363.8            1.87
  AJ222813_s\_at         interleukin 18                                            82.2               374.6            1.74
  D89069_f\_at           carbonyl reductase 1                                      705.1              3095.2           1.74
  U46118_at              cytochrome P450, family 3, subfamily a, polypeptide 13    138.3              386.3            1.74
  AFFX_Rat_GAPDH_3\_at   glyceraldehyde-3-phosphate dehydrogenase (GAPDH)          964.7              3448.5           1.62
  D17310_s\_at           3-alpha-hydroxysteroid dehydrogenase                      129.1              484.7            1.62
  rc_AA926193_at         sulfotransferase family, cytosolic, 1C, member 2          523.4              1761.8           1.62
  rc_AI171243_at         replication protein A3 (predicted)                        61.7               195.5            1.62
  rc_AI175959_at         v-jun sarcoma virus 17 oncogene homolog (avian)           121.3              345.4            1.62
  rc_AI177256_at         moderately similar to NP_795929.1 RIKEN cDNA 8030475D13   512.5              2134.4           1.62
  rc_AA900199_s\_at      NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6      269.7              775.7            1.52
  rc_AA945054_s\_at      cytochrome b-5                                            271.0              1003.5           1.52
  rc_AA945867_at         v-jun sarcoma virus 17 oncogene homolog (avian)           88.3               307.0            1.52
  rc_AI013834_s\_at      hydroxysteroid (17-beta) dehydrogenase 4                  127.8              415.9            1.52
  Z78279_g\_at           collagen, type 1, alpha 1                                 593.3              2153.6           1.52
